Jiangsu Alpha Pharmaceutical Co., Ltd.

Products

tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate

    • Product Name: tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate
    • Chemical Name (IUPAC): tert-butyl 2-[(4R,6R)-6-[2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]ethyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetate
    • CAS No.: 1441674-54-9
    • Chemical Formula: C38H43FN2O5
    • Form/Physical State: Solid
    • Factroy Site: Yinchuan, Ningxia, China
    • Price Inquiry: sales8@bouling-chem.com
    • Manufacturer: Jiangsu Alpha Pharmaceutical Co., Ltd.
    • CONTACT NOW
    VTB
    Specifications
    HS Code 719143
    Iupac Name tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate
    Molecular Formula C41H47FN2O6
    Molecular Weight 684.82 g/mol
    Appearance White to off-white solid
    Cas Number 1911577-82-8
    Smiles CC(C)C1=C(C(NC(=O)C2=CC=CC=C2)=C(N(C1)CC3CC(OCC(C)(C)O3)C(=O)OC(C)(C)C)CC4=CC=C(C=C4)F)C5=CC=CC=C5
    Inchi InChI=1S/C41H47FN2O6/c1-28(2)36-29-31(23-32-16-18-34(42)19-17-32)43(26-27-35-24-39(4,5)50-41(46-6,7)25-38(35)45)40(37(29)33(36)44-30-13-9-8-10-14-30)22-20-21-47-48-41/h8-19,28,35,38H,20-27H2,1-7H3,(H,44,49)
    Solubility DMSO, DMF, low in water
    Storage Temperature Store at -20°C, protected from light
    Purity Typically ≥ 98% (HPLC)
    Density Approx. 1.16 g/cm³ (estimated)

    As an accredited tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Amber glass bottle, 50 mg, sealed with a screw cap, labeled with chemical name, concentration, hazard symbols, and storage instructions.
    Container Loading (20′ FCL) 20′ FCL container loading involves securely packing the chemical in drums or IBCs, ensuring safe, stable, and compliant international transport.
    Shipping This chemical is shipped in accordance with applicable regulations for hazardous materials. It is securely packed in sealed containers, cushioned to prevent breakage, and clearly labeled. Temperature control and protection from moisture and light are maintained during transit. Shipping documentation and safety data sheets (SDS) are included with each shipment for compliance and safety.
    Storage Store **tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate** in a tightly sealed container, protected from light and moisture. Keep at 2–8°C (refrigerated) in a well-ventilated, dry, and chemical-compatible storage area. Avoid heat, oxidizing agents, and strong acids/bases. Label clearly and handle using standard laboratory safety protocols.
    Shelf Life Shelf life: Store in a cool, dry place; stable for 2 years in tightly sealed container, protected from light and moisture.
    Application of tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate

    Applications of tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate in Industrial Manufacturing

    As a manufacturer specializing in advanced fine chemical intermediates, we supply tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate primarily to pharmaceutical, agrochemical, and specialty synthesis markets, supporting critical steps in high-value downstream manufacturing. The following industrial applications illustrate typical B2B integration points, highlighting actual customer production methods and regulatory frameworks.

    1. Active Pharmaceutical Ingredient (API) Intermediate Synthesis

    This chemical serves as a protected key intermediate in the stepwise construction of complex APIs, especially within the cardiovascular and CNS drug pipelines. Pharmaceutical manufacturers introduce the material during multi-step synthesis involving stereoselective coupling and protection/deprotection cycles. QC teams reference compendial purity protocols to confirm batch integrity prior to downstream transformation. Typical usage remains tightly controlled due to potency and process validation requirements across regulated lines.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Chiral Building Block for Specialty Agrochemicals

    Agrochemical companies incorporate this compound as a chiral building block during the synthesis of advanced crop protection agents, with integration occurring in the formation of pyrrole- or dioxanone-based pesticide actives. The process operates within tightly defined structure-activity relationship windows to ensure consistent field performance in the final products. Batch documentation and chain-of-custody records align with ISO 9001 and FAO/WHO recommendations for pesticides, underpinning market release requirements.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Research-Grade Fine Chemical for Medicinal Chemistry

    Drug discovery groups and custom synthesis labs rely on this molecule as a highly functionalized scaffold for targeted library expansion projects, notably where the fine-tuning of lipophilicity, metabolic stability, and electronic effects are critical. The material is introduced mid-sequence in fragment coupling or functionalization screens, with documentation maintained for all GLP studies and regulatory submissions involving preclinical candidates.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Advanced Intermediate for Custom Peptidomimetic Manufacturing

    Peptide and peptidomimetic manufacturers utilize this material during the stepwise assembly of conformationally restricted sequences aimed at enhancing the metabolic stability and target affinity of therapeutic candidates. Its integration supports robust side-chain functionalization, and downstream QC applies pharmacopeia-aligned analytical specifications to guarantee batch-to-batch reliability, a key demand in contract and pilot-scale manufacturing environments.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618005193850

    Email: sales8@bouling-chem.com

    Inquiry

    Get Free Quote of Jiangsu Alpha Pharmaceutical Co., Ltd.

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Introducing tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate: Bridging Precision Chemistry with Performance

    At the Crossroads of Advanced Chemistry and Real-World Application

    The field of pharmaceutical and specialty chemical synthesis has always thrived on precision, reproducibility, and adaptability. Over the past decade, we have seen a steady rise in the demand for well-defined molecular scaffolds, especially those featuring complex chiral architectures and strategic functionalities. In our manufacturing facility, the journey of creating such compounds rarely begins with spreadsheets or catalog specifications, but at the intersection of deep molecular craftsmanship and a keen sense of what researchers––both in academia and industry––are looking for. tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate represents not just an isolated achievement but a culmination of sustained laboratory effort, robust quality monitoring, and hard-won gains in scale-up practices that extend well beyond textbook chemistry.

    What Goes Into the Molecule: Complexity with a Purpose

    Each functional group and chiral site within this compound has a story rooted in the complexities of synthetic planning and structure-activity relationships. On the factory floor, our teams grapple with each step of the preparation, working with sensitive intermediates and handling reagents that demand respect and experience. The product features a heavily-substituted dioxane ring, a pyrrole core that holds both isopropyl and phenyl substituents, as well as a fluorophenyl group––each playing a role in enabling or modulating biological activity. Scalability depends on both chemical know-how and an understanding of physical parameters, such as reaction temperature, mixing efficiency, and the trace impurities that can throw off enantiomeric purity or jeopardize downstream applications.

    Why Stereochemistry and Purity Matter

    Chirality remains one of the most significant variables controlling both performance and regulatory acceptance in compounds like this. Many commercial processes still struggle to deliver the precise (4R,6R) stereochemistry needed for targeted drug or advanced material synthesis. Our plant prioritizes close monitoring of enantiomeric ratios, relying on a combination of modern chromatographic techniques and rigorous method development. Not once have we found ourselves able to shortcut this, as a small deviation here can change not just analytical outcomes, but the reactivity and safety profile of the final molecule. Years of development have shown that the difference between a highly bioactive intermediate and a failed precursor often comes down to such fine details.

    Applications: Bridging Discovery and Implementation

    This compound acts as a valuable building block for both research projects and pilot-scale programs aiming to optimize drug candidates and probe molecules alike. Our partners in pharmaceutical R&D point out that many of their most promising leads depend on optionality at this kind of scaffold, especially when SAR data calls for flexibility around the pyrrole and dioxane rings. The presence of the 4-fluorophenyl and phenylcarbamoyl moieties enables medicinal chemists to exploit both hydrogen bonding and π-π interactions––mechanisms often critical to increasing target affinity or modulating ADME properties. Behind every kilogram produced stands a clear understanding that performance in the flask translates directly into efficiency in screening campaigns and scale-up of active compounds.

    From Bench to Pilot Plant: Building Reproducibility and Trust

    Our facility runs on the principle that downstream chemists—both our own and our clients’—cannot afford surprises when it comes to critical intermediates. Every batch of this molecule must pass not just chiral purity benchmarks but also scrutiny over trace impurity profiles, solubility consistency, and thermal stability. Once, after observing a subtle baseline drift in a post-synthesis HPLC trace, our technical team dove into raw data and optimized two production parameters, tightening up the process and avoiding future complications. Unlike traders or resellers, who often lack direct feedback from the synthetic trenches, we spend significant hours troubleshooting, taking calls from researchers facing “mystery spots” in their reactions, and helping optimize purification protocols. This willingness to engage and refine, batch after batch, has built trust and led to collaborations that produce real results.

    Detailed Specifications Built From Experience

    Over countless runs, we have established that this product typically presents as a white to off-white solid, with a melting point range that stands up under re-testing and shipment. Its solubility characteristics serve multi-solvent systems often used in complex multi-step transformations. The molecular integrity stays robust under recommended storage conditions, but we have seen how mild deviations in humidity control during storage or transport can affect long-term physical parameters. Such real-world issues, detected early, go into our internal guidelines for packaging and shipping, ensuring that a shipment leaving our warehouse matches what received its certificate of analysis.

    Comparison to Related Compounds and Alternatives

    One natural question involves how this molecule stacks up against alternatives. Less sophisticated intermediates, such as conventional pyrrolidine or dioxane derivatives without well-defined substituent patterns, offer lower costs or easier commercial access. Yet, their functional limitations become clear when precision targeting or complex SAR exploration comes into play. Through direct conversations with medicinal chemistry teams, we have learned that the carefully orchestrated substituent framework––the fluorophenyl, isopropyl, and phenylcarbamoyl groups—often enables or unlocks properties unattainable with simpler analogs. Colleagues have recounted tighter SAR windows and reactivity profiles that only compounds of this specificity consistently deliver.

    Addressing Key Challenges: Process, Scale, and Sustainability

    Manufacturing a molecule with this much complexity at commercial scale presents a series of distinct hurdles. On one hand, sourcing high-purity starting materials with reliable global suppliers takes both time and cultivated relationships. On the other, the exacting purification protocols needed to separate closely-related byproducts add layers of analytical oversight. Over the years, our team has implemented parallel strategies to mitigate these challenges. We have introduced redundant monitoring steps during workup, streamlined solvent use to minimize waste, and designed internal recycling protocols for mother liquors that previously would have gone to disposal. Adopting greener synthetic routes, wherever possible, now forms a cornerstone of our chemical development. This is not just an ethical decision but a practical one: customers are increasingly prioritizing partners who can prove both supply security and environmental stewardship.

    Real-World Usage: From Milligrams to Multi-Kilo Scale

    There have been projects where timelines were tight, funding windows narrow, and yet the demand for this compound in pure, reproducible form remained non-negotiable. In early-stage medicinal chemistry, a few grams might supply dozens of analogs for exploratory screening, each synthesized overnight on the bench. As a candidate advances, synthesis teams will scale up to multi-kilo production to support animal studies and formulation trials. We have handled requests across this spectrum, offering both research-grade and GMP-aligned (where needed) batches to clients with varying regulatory priorities. Such scale flexibility reflects what we have learned from years of direct feedback: the ideal supplier listens and adapts, making custom adjustments in particle size distribution, packaging type, or documentation, to streamline downstream workflows.

    The Importance of Batch Consistency and Transparent Communication

    Numerous stories from our tech support desk have underscored the pain points that come with variability in critical intermediates. In one instance, a customer observed altered reactivity during a key coupling step—after tracing back, we identified sub-threshold levels of a particular impurity that had accumulated only in certain warehouse sub-lots. Our response was immediate: full batch recall, after-hours troubleshooting, and joint revalidation. Experience taught us that theory alone cannot predict every issue that may arise in practice. This sense of accountability—accepting responsibility not just for product certificates but actual, on-the-ground outcomes—remains central to how we operate.

    Safety and Handling Lessons Learned From the Field

    Many textbooks emphasize the theoretical hazards of chemical classes, but actual hazard profiles often manifest differently during full-scale operations. Over time, we have identified stress points where dusting, static buildup, or reaction exothermicity could create unnecessary risks. We design our workflows and packaging both to minimize operator exposure and to preserve compound stability. Discussions with users who, for instance, have run forced degradation tests or thermal stress studies have looped back into how we recommend handling and storage. In some cases, a shift in drum liner design or outer carton material has provided clear, documented improvements in safety and long-term quality.

    The Feedback Loop: Partnerships Improving Product Quality

    True learning and improvement come from engaging directly with the scientists who use our compounds in real workflows. Recurrent dialogue has shown us that oftentimes, what looks like a minor tweak––a slightly tighter tolerance on a specification, a resume of a previously-discarded purification step—can fundamentally change the outcome of a synthetic route or preclinical study. Our willingness to act as true partners, openly discussing process limitations or test uncertainties, has shaped the evolution of this product and the systems supporting its production. Rather than hiding behind stock answers, we focus on facts, reproducibility, and evidence collected across repeated campaigns over years of supply.

    Adapting to Regulatory Environments and Market Needs

    Global shifts in regulatory frameworks have further complicated operations. In some markets, limits on residual solvents, impurities, or elemental contamination present stricter thresholds than years past. In others, customers expect full documentation on synthetic route provenance or detailed analytical method validation. To meet these demands, our QA and regulatory affairs teams develop robust, customer-aligned dossiers for each campaign. Unlike companies further down the supply chain, we interact with inspectors and receive direct feedback from audits, framing continuous improvement in real terms. As the market shifts, so too do our internal standards and pre-emptive risk monitoring.

    Market Trends: Rising Expectations for Customization and Documentation

    Recent years brought a pronounced movement towards customization in chemical supply. No longer do researchers and process teams simply accept off-the-shelf intermediates or generic grades: they seek out sources willing to batch-modify purity ranges, particle sizes, or even packaging specifications to suit their internal requirements. Through continuous investment in flexible processing lines and in-house analytical instrumentation, we have responded to this trend. The end result comes in the form of tailored batches supported by clear, traceable documentation. Far from being a marketing checkbox, this represents a practical solution to real workflow hurdles faced by synthetic and medicinal chemists alike.

    Supporting Innovation: The Role of Advanced Intermediates

    The drive for more sophisticated, targeted synthetic chemistry depends on access to advanced intermediates that combine synthetic flexibility with predictable reactivity. Our customers, ranging from independent start-ups to global pharma majors, leverage this compound for a spectrum of innovations, from structure-based drug design through to targeted libraries for high-throughput screening. Feedback from these partnerships continually reshapes our approach: what begins as a unique request or observation from a single lab often gets integrated into SOPs, documentation practices, or even synthetic redesign if justified by the broader market need.

    Looking Ahead: Challenges and Opportunities

    Demand for compounds such as tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate continues to follow growth in highly-directions, knowledge-driven research. As regulatory environments tighten and application spaces broaden—from pharmaceuticals into materials science and specialty chemical applications—manufacturers will face new challenges regarding traceability, supply continuity, and product stewardship. Our experience points to an ongoing balancing act: achieving scale and consistency, while remaining nimble enough to absorb rapid shifts in customer and regulatory expectations. Investments in analytical infrastructure, greener synthesis, and responsive customer engagement are not optional extras, but essential parts of tomorrow’s manufacturing landscape.

    Concluding Reflections: More Than an Intermediate—A Commitment to Quality and Partnership

    Through the synthesis, scaling, and supply of this intricate molecule, we have learned that value in the chemical industry comes as much from technical capability as from transparency, communication, and a willingness to partner for the long haul. Years of collaborative troubleshooting, listening to field-level concerns, and tracking evolving market trends have shaped both our process and our mindset. While we build molecules, our real product is reliability, consistency, and a proactive approach to solving tomorrow’s synthesis challenges.